

Supplementary Table 2: Summary of clinical and pathological characteristics of the primary ovarian cancer cells established from patient ascites

Patient	Age at Diagnosis (years)	Stage at Diagnosis	Diagnosis	1st line treatment	Chemosensitive
1	46	IIIC	Serous papillary carcinoma of the ovary	Carboplatin & Paclitaxel	Yes
2	66	IV	Recurrent ovarian carcinoma	Carboplatin & Paclitaxel	Yes
3	66	IIIC	Serous carcinoma of ovary/peritoneum	Carboplatin & Paclitaxel	Yes
4	60	IIIC	Serous papillary carcinoma of the ovary	Carboplatin & Paclitaxel	Yes
5	80	IIIC	Serous papillary carcinoma of the ovary	Carboplatin	Yes
6	72	IIIC	Serous papillary carcinoma of the ovary	Carboplatin & Paclitaxel	Yes
7	61	IIIA	Papillary serous carcinoma of the ovary	Carboplatin & Paclitaxel	Yes
8	58	IIIC	Serous papillary carcinoma of the ovary	Carboplatin & Paclitaxel	Yes
9	66	IIIC	Serous papillary carcinoma of the ovary	Carboplatin & Paclitaxel	Yes
10	85	IIIC	Serous papillary carcinoma of the ovary	Carboplatin / Paclitaxel + Caelyx	No
11	47	IIIC	Recurrent serous carcinoma of the ovary	Carboplatin & Paclitaxel	No
12	69	IIIA	Recurrent serous ovarian cancer	Carboplatin & Paclitaxel	No
13	59	IA	Recurrent serous tubal	No chemotherapy	No
14	43	IIC	Recurrent serous peritoneal carcinoma	Carboplatin & Paclitaxel	No
15	57	-	Recurrent serous carcinoma	Carboplatin & Paclitaxel	No